UY25936A1 - Formulaciones medicamentosas retardadas que contienen una combinación de un opioide y alfa-agonista - Google Patents

Formulaciones medicamentosas retardadas que contienen una combinación de un opioide y alfa-agonista

Info

Publication number
UY25936A1
UY25936A1 UY25936A UY25936A UY25936A1 UY 25936 A1 UY25936 A1 UY 25936A1 UY 25936 A UY25936 A UY 25936A UY 25936 A UY25936 A UY 25936A UY 25936 A1 UY25936 A1 UY 25936A1
Authority
UY
Uruguay
Prior art keywords
agonist
alpha
clonidine
opioid
physiologically tolerable
Prior art date
Application number
UY25936A
Other languages
English (en)
Inventor
Johannes Bartholomaeus
Juergen Betzing
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of UY25936A1 publication Critical patent/UY25936A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulaciones medicamentosas retardadas que contienen una combinación de un opioide o una sal fisiológicamente tolerable del mismo, y un alfa-agonista o una sal fisiológicamente tolerable del mismo, conjuntamente con lactosa o fosfato monoácido cálcico, con o sin otros excipientes farmacéuticos, así como su uso en estados álgidos de mediana intensidad hasta agudos severos o crónicos. Los opioides están elegidos del grupo que comprende morfina, hidromorfona, codeína, oxicodona, dihidrocodeína, dextropropoxifen, buprenorfina, levometadona, fentanil, sufentanil, etorfina, pentazocina, tilidina, tramadol, levorfanol, metadona, dihidromorfina, petidina, piritramida o una sal fisiológicamente aceptable de los mismos. El alfa-agonista se selecciona del grupo que comprende clonidina, guanfacina, guanabenz, lofexidina, adrenalina, metildopa, noradrenalina, metoxamina, oximetazolina, xilometazolina, terizolina, medetomidina, dexmedetomidina, agmatina, para-amino-clonidina, xilazina, talipexol, nafazolina, tizanidina o una sal fisiológicamente tolerable de los mismos.
UY25936A 1999-01-18 2000-01-17 Formulaciones medicamentosas retardadas que contienen una combinación de un opioide y alfa-agonista UY25936A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19901684 1999-01-18

Publications (1)

Publication Number Publication Date
UY25936A1 true UY25936A1 (es) 2001-07-31

Family

ID=7894563

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25936A UY25936A1 (es) 1999-01-18 2000-01-17 Formulaciones medicamentosas retardadas que contienen una combinación de un opioide y alfa-agonista

Country Status (15)

Country Link
US (1) US20020044966A1 (es)
EP (1) EP1143936A2 (es)
JP (1) JP2002534458A (es)
AR (1) AR022252A1 (es)
AU (1) AU772886B2 (es)
BR (1) BR0000578A (es)
CA (1) CA2359273A1 (es)
CO (1) CO5160243A1 (es)
HU (2) HUP0105043A3 (es)
NO (2) NO20000225D0 (es)
NZ (1) NZ513501A (es)
PE (1) PE20001396A1 (es)
SK (1) SK10012001A3 (es)
UY (1) UY25936A1 (es)
WO (1) WO2000041681A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2374717T3 (es) 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CA2424021A1 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine compositions and uses thereof
KR100960200B1 (ko) 2000-10-30 2010-05-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
EP1395243A2 (en) * 2001-05-31 2004-03-10 SkyePharma Inc. Encapsulation of nanosuspensions in liposomes and microspheres
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
KR20030034171A (ko) * 2001-07-06 2003-05-01 엔도 파마슈티걸즈, 인크. 옥시모르폰 제어 방출 제형
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US7854230B2 (en) * 2001-10-22 2010-12-21 O.R. Solutions, Inc. Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US7648981B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US7648982B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
US7485323B2 (en) * 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
NZ565649A (en) * 2005-07-28 2011-03-31 Shire Llc Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
JP5269595B2 (ja) 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US20090087490A1 (en) 2007-06-08 2009-04-02 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
WO2009130715A1 (en) * 2008-04-25 2009-10-29 Cadila Healtcare Limited Rapidly disintegrating oral compositions of tramadol
EP2309993A1 (en) * 2008-06-25 2011-04-20 US Worldmeds LLC Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
US8603497B2 (en) * 2008-10-30 2013-12-10 National University Corporation Okayama University Composition for local anesthesia
NZ600640A (en) * 2009-12-17 2014-11-28 Cima Labs Inc Abuse-resistant formulations
EP2568977A1 (en) 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms
SG10201510564PA (en) 2010-12-22 2016-01-28 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
CA2850964C (en) 2011-10-05 2021-02-02 Jennifer L. Sanders Methods and compositions for treating foot or hand pain
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
EP3054935B1 (en) 2013-10-07 2020-12-09 Teikoku Pharma USA, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
RU2646512C2 (ru) 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
RU2648449C2 (ru) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN112494486B (zh) * 2020-12-07 2022-01-21 深圳善康医疗健康产业有限公司 一种用于减轻或消除阿片戒断综合症的药物组合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946848A (en) * 1985-10-29 1990-08-07 Baker Cumins Dermatologicals, Inc. Method of treating pruritus with nalmefene and clonidine
PT99629A (pt) * 1991-11-28 1993-05-31 Antonio Feria Reis Valle Metodo de desintoxicacao de opiaceos
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
DE19758564A1 (de) * 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung

Also Published As

Publication number Publication date
US20020044966A1 (en) 2002-04-18
BR0000578A (pt) 2001-08-14
AU2109000A (en) 2000-08-01
EP1143936A2 (de) 2001-10-17
JP2002534458A (ja) 2002-10-15
WO2000041681A3 (de) 2000-12-07
NO20013302D0 (no) 2001-07-03
PE20001396A1 (es) 2000-12-23
WO2000041681A2 (de) 2000-07-20
NO20000225D0 (no) 2000-01-17
AR022252A1 (es) 2002-09-04
CO5160243A1 (es) 2002-05-30
HUP0105043A2 (en) 2002-06-29
HUP0105043A3 (en) 2005-06-28
HU0000139D0 (en) 2000-03-28
NO20013302L (no) 2001-07-03
SK10012001A3 (sk) 2002-01-07
AU772886B2 (en) 2004-05-13
CA2359273A1 (en) 2000-07-20
NZ513501A (en) 2003-11-28

Similar Documents

Publication Publication Date Title
UY25936A1 (es) Formulaciones medicamentosas retardadas que contienen una combinación de un opioide y alfa-agonista
WO2004045551A3 (en) Pharmaceutical composition
TW200514581A (en) In-situ gelling drug delivery system
BRPI0418228A (pt) forma de dosagem, e, métodos de tratamento de dor e de episódios de dor incidente de cáncer, e de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil
WO2003090726A3 (en) Chewable soft capsule
US20240350479A1 (en) Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
PE20050146A1 (es) Forma de dosificacion transdermica resistente a la manipulacion
AR076540A1 (es) Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de analgesicos no- opioides y opioides, forma de dosificacion. metodo de preparacion. metodo para tratar dolor
WO2007061828A3 (en) Pharmaceutical compositions comprising buprenorphine
EA201400246A1 (ru) Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
MXPA04003597A (es) Conjugados polimericos de antagonistas opiaceos.
TR200103302T2 (tr) Diamorfin etkin maddeli farmasötik preparat
ES2963078T3 (es) Formulaciones de liberación inmediata disuasorias del abuso que comprenden polisacáridos no celulósicos
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
RS54764B1 (sr) Sredstvo za transmukozalnu isporuku sa povećanim nakupljanjem
BRPI0606247A2 (pt) uso de oxicodona para tratamento da dor visceral
ATE500821T1 (de) Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
CY1109031T1 (el) Τριαζασπιρο ενωσεις χρησιμες για την αντιμετωπιση ή προληψη πονου
TR201002473A2 (tr) Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
ES2239928T1 (es) Metodo para reducir el dolor utilizando virus oncoliticos.
WO2012166891A3 (en) Mu-opioid receptor binding compounds
NZ599957A (en) Drug combination with theobromine and its use in therapy
US20180193331A1 (en) Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
AR051087A1 (es) Sistema para la administracion transdermica secuencial de sustancias con actividad sistemica

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20100111